TSX higher on employment data
Spero Therapeutics NASDAQ:SPRO Chief Operating Officer Timothy Keutzer sold 1,695 shares of common stock on August 28, 2025, at a price of $1.97, for a total transaction value of $3,339. The transaction comes as the stock trades near its InvestingPro Fair Value, following an impressive 166% surge over the past six months.
According to a Form 4 filing with the Securities and Exchange Commission, the sale was executed to cover tax withholding obligations related to the vesting of restricted stock units granted to Keutzer on August 26, 2021. Following the transaction, Keutzer directly owns 739,744 shares of Spero Therapeutics . InvestingPro analysis reveals the company maintains strong liquidity with a current ratio of 3.97, though analysts anticipate sales decline in the current year. Get access to 8 more key ProTips and a comprehensive research report for SPRO on InvestingPro.
The sale was reported on September 2, 2025, under a signature from Maegan Deare, Attorney-in-Fact for Timothy Keutzer.
In other recent news, Spero Therapeutics Inc. reported earnings for the second quarter of 2025 that surpassed analyst expectations. The company achieved an earnings per share (EPS) of -$0.03, significantly better than the anticipated -$0.57, marking a 94.74% surprise. Additionally, Spero Therapeutics recorded revenue of $14.2 million, exceeding the forecasted $11 million. These results highlight strong performance in both earnings and revenue for the quarter. While the stock experienced a rise following the announcement, this article focuses on the company’s financial results rather than stock movements. Analyst commentary on the results was not explicitly detailed in the recent updates. These developments reflect the company’s ongoing financial activities and performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.